Giant Shape-Persistent Tetrahedral Porphyrin System: Light-Induced Charge Separation

Tetraphenylmethane appended with four pyridylpyridinium units works as a scaffold to self-assemble four ruthenium porphyrins in a tetrahedral shape-persistent giant architecture. The resulting supramolecular structure has been characterised in the solid state by X-ray single crystal analysis and in solution by various techniques. Multinuclear NMR spectroscopy confirms the 1 : 4 stoichiometry with the formation of a highly symmetric structure. The self-assembly process can be monitored by changes of the redox potentials, as well as by modifications in the visible absorption spectrum of the ruthenium porphyrin and by a complete quenching of both the bright fluorescence of the tetracationic scaffold and the weak phosphorescence of the ruthenium porphyrin. An ultrafast photoinduced electron transfer is responsible for this quenching process. The lifetime of the resulting charge separated state (800 ps) is about four times longer in the giant supramolecular structure compared to the model 1 : 1 complex formed by the ruthenium porphyrin and a single pyridylpyridinium unit. Electron delocalization over the tetrameric pyridinium structure is likely to be responsible for this effect

European Code against Cancer 4th Edition:Breastfeeding and cancer

Breast cancer is the most frequent cancer in women, and incidence rates have been rising in European Union (EU) countries over recent decades due in part to a sharp decline in breastfeeding practices. Evidence for a protective association between breastfeeding and the risk of breast cancer at all ages is convincing, and modest protective relationships between breastfeeding and the risk of endometrial and ovarian cancers have been suggested. The reduction in breast cancer risk is estimated at 2% for an increase of 5 months of lifetime breastfeeding. The longer women breastfeed, the more they are protected against breast cancer. In addition, breastfeeding is associated with several health benefits for both the mother and the breastfed child. Taking all this evidence into account, the 4th edition of the European Code against Cancer recommends: ‘‘Breastfeeding reduces the mother’s cancer risk. If you can, breastfeed your baby’’

European code against cancer 4th edition: 12 ways to reduce your cancer risk

This overview describes the principles of the 4th edition of the European Code against Cancer and provides an introduction to the 12 recommendations to reduce cancer risk. Among the 504.6 million inhabitants of the member states of the European Union (EU28), there are annually 2.64 million new cancer cases and 1.28 million deaths from cancer. It is estimated that this cancer burden could be reduced by up to one half if scientific knowledge on causes of cancer could be translated into successful prevention. The Code is a preventive tool aimed to reduce the cancer burden by informing people how to avoid or reduce carcinogenic exposures, adopt behaviours to reduce the cancer risk, or to participate in organised intervention programmes. The Code should also form a base to guide national health policies in cancer prevention. The 12 recommendations are: not smoking or using other tobacco products; avoiding second-hand smoke; being a healthy body weight; encouraging physical activity; having a healthy diet; limiting alcohol consumption, with not drinking alcohol being better for cancer prevention; avoiding too much exposure to ultraviolet radiation; avoiding cancer-causing agents at the workplace; reducing exposure to high levels of radon; encouraging breastfeeding; limiting the use of hormone replacement therapy; participating in organised vaccination programmes against hepatitis B for newborns and human papillomavirus for girls; and participating in organised screening programmes for bowel cancer, breast cancer, and cervical cancer

European Code against Cancer, 4th Edition: Cancer screening

In order to update the previous version of the European Code against Cancer and formulate evidence-based recommendations, a systematic search of the literature was performed according to the methodology agreed by the Code Working Groups. Based on the review, the 4th edition of the European Code against Cancer recommends: “Take part in organized cancer screening programmes for: • Bowel cancer (men and women)• Breast cancer (women)• Cervical cancer (women).”Organized screening programs are preferable because they provide better conditions to ensure that the Guidelines for Quality Assurance in Screening are followed in order to achieve the greatest benefit with the least harm. Screening is recommended only for those cancers where a demonstrated life-saving effect substantially outweighs the potential harm of examining very large numbers of people who may otherwise never have, or suffer from, these cancers, and when an adequate quality of the screening is achieved. EU citizens are recommended to participate in cancer screening each time an invitation from the national or regional screening program is received and after having read the information materials provided and carefully considered the potential benefits and harms of screening. Screening programs in the European Union vary with respect to the age groups invited and to the interval between invitations, depending on each country's cancer burden, local resources, and the type of screening test used For colorectal cancer, most programs in the EU invite men and women starting at the age of 50–60 years, and from then on every 2 years if the screening test is the guaiac-based fecal occult blood test or fecal immunochemical test, or every 10 years or more if the screening test is flexible sigmoidoscopy or total colonoscopy. Most programs continue sending invitations to screening up to the age of 70–75 years. For breast cancer, most programs in the EU invite women starting at the age of 50 years, and not before the age of 40 years, and from then on every 2 years until the age of 70–75 years. For cervical cancer, if cytology (Pap) testing is used for screening, most programs in the EU invite women starting at the age of 25–30 years and from then on every 3 or 5 years. If human papillomavirus testing is used for screening, most women are invited starting at the age of 35 years (usually not before age 30 years) and from then on every 5 years or more. Irrespective of the test used, women continue participating in screening until the age of 60 or 65 years, and continue beyond this age unless the most recent test results are normal

Screening for colorectal cancer with endoscopy in the average risk population

Plusieurs études ont montré que la formation des cancers colorectaux s'échelonne sur plusieurs années, à partir de lésions prémalignes constituées pour la plupart de polypes adénomateux. Les arguments en faveur de l'instauration de programmes généralisés pour les sujets asymptomatiques à risque moyen utilisant des techniques endoscopiques s'appuient sur les résultats des études qui ont démontré une diminution de la mortalité et de l'apparition de carcinomes après polypectomies. Plusieurs études cas-témoins confirment l'efficacité préventive du dépistage par sigmoïdoscopie. L'effet protecteur de l'examen endoscopique se manifesterait pendant 10 ans. Deux techniques sont utilisées à des fins de dépistage: la sigmoïdoscopie et la coloscopie. Elles peuvent servir tout autant au dépistage qu'aux procédures diagnostiques et thérapeutiques. Nous avons comparé la performance de ces techniques en termes d'acceptabilité, taux de complications, proportion de lésions détectables, et coûts. Les deux procédures ne sont pas identiques dans un contexte de dépistage. La coloscopie permet de révéler aussi des lésions proximales qui auraient échappé à la sigmoïdoscopie, mais différents facteurs restreignent son utilisation à grande échelle dans le cadre d'un dépistage : la nécessité d'une bonne formation pour les coloscopistes, les coûts, les taux de complications, l'acceptabilité par la population cible

Shoreline Detection from PRISMA Hyperspectral Remotely-Sensed Images

Coastal managers, policymakers, and scientists use shoreline accretion/erosion trends to determine the coastline’s historical evolution and generate models capable of predicting future changes. Different solutions have been developed to obtain shoreline positions from Earth observation data in recent years, the so-called Satellite-Derived Shorelines (SDS). Most of the methodologies available in the literature use multispectral optical satellite imagery. This paper proposes two new methods for shoreline mapping at the subpixel level based on PRISMA hyperspectral imagery. The first one analyses the spectral signatures along defined beach profiles. The second method uses techniques more commonly applied to multispectral image analysis, such as Spectral Unmixing algorithms and Spatial Attraction Models. The results obtained with both methodologies are validated on three Mediterranean microtidal beaches located in two different countries, Italy and Greece, using image-based ground truth shorelines manually photointerpreted and digitised. The obtained errors are around 6 and 7 m for the first and second methods, respectively. These results are comparable to the errors obtained from multispectral data. The paper also discusses the capability of the two methods to identify two different shoreline proxies

A tailored RAFT copolymer for the dispersion of single walled carbon nanotubes in aqueous media

The Reversible Addition-Fragmentation chain-Transfer (RAFT) synthesis of poly(glycidyl methacrylate) (PGMA) copolymers followed by the post-polymerisation treatment with morpholine allows the rational design of amphiphilic block copolymers that are capable of efficiently dispersing single walled carbon nanotubes (SWCNTs) in aqueous media, as shown by comparative photophysical characterisation and AFM analysis